Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study

Fibromyalgia patients from a long-term, open-label study of milnacipran (50-200 mg/day) were eligible to participate in a 12-week, randomized, placebo-controlled withdrawal study. The withdrawal study evaluated loss of therapeutic response in patients who achieved ≥50% pain improvements after receiv...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pain research 2014-01, Vol.7 (default), p.679-687
Main Authors: Mease, Philip J, Clauw, Daniel J, Trugman, Joel M, Palmer, Robert H, Wang, Yong
Format: Article
Language:English
Subjects:
Arthritis
Clinical trials
Diabetes
Double-blind studies
Drug therapy
Fatigue
Fibromyalgia
Health surveys
Original Research
Pain
Patients
Population
post-hoc analysis
Questionnaires
responders
Studies
symptoms
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Fibromyalgia patients from a long-term, open-label study of milnacipran (50-200 mg/day) were eligible to participate in a 12-week, randomized, placebo-controlled withdrawal study. The withdrawal study evaluated loss of therapeutic response in patients who achieved ≥50% pain improvements after receiving up to 3.25 years of milnacipran. This post-hoc analysis investigated whether patients who met lower thresholds of pain improvement also experienced worsening of fibromyalgia symptoms upon treatment withdrawal. Among patients who received milnacipran ≥100 mg/day during the long-term study, three subgroups were identified based on percentage of pain reduction at randomization: ≥50% (protocol-defined "responders"; n=150); ≥30% to
ISSN:1178-7090
1178-7090
DOI:10.2147/JPR.S70200